Either the content you're seeking doesn't exist or it requires proper authentication before viewing.
Developed by ISCT Business Development & Finance Committee The year 2025 marked a notable period of momentum for the cell and gene therapy (CGT) sector, characterised by significant deal making across multiple therapeutic modalities. In 2025, ...
Fajar Dumadi, BSc International Society for Cell & Gene Therapy (ISCT) Canada Following the release of the latest edition of the ISCT CGT Global Regulatory Report —presenting a comprehensive year-end review of 2025—we are proud to share a significant ...
Tuula Rintala Director, Quality of Care and Advocacy EBMT, European Society for Blood and Marrow Transplantation Spain CAR-T cell therapy has transformed the treatment landscape for patients with haematological malignancies, but its promise can ...
Introduction In the rapidly evolving landscape of advanced therapies, few challenges are as complex — or as consequential — as scaling cell therapy manufacturing to meet growing clinical and commercial demand. In this expert analysis, the team ...
Madhavi Lakkaraja, MD, MPH Fred Hutchinson Cancer Center, University of Washington School of Medicine United States From ISCT 2025 Roundtable Session: Cell Therapies to Manage GVHD - Learning From Pivotal Approvals 1. How the Biology of Acute ...